Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. (2nd January 2018)

• Record Type: Journal Article
• Authors: Cicero, Arrigo F.G.; Bove, Marilisa; Borghi, Claudio
• Is Part Of: Expert opinion on drug metabolism and toxicology. Volume 14:Number 1(2018)
• Page Start: 9
• Page End: 15
• Publication Date: 2018-01-02
• Subjects: LDL-cholesterol -- cardiovascular risk -- LDL-cholesterol-lowering -- ezetimibe -- Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors -- Cholesteryl Ester Transfer Protein (CETP) inhibitor -- Microsomal triglyceride Transfer Protein (MTP) inhibitor; Drugs -- Toxicology -- Periodicals; Drugs -- Metabolism -- Periodicals; 615.7
• DOI: 10.1080/17425255.2018.1416094
• Languages: English
• ISSNs: 1742-5255

Abstract

ABSTRACT: Introduction : Hypercholesterolemia is the main modifiable risk factor for atherosclerosis progression and cardiovascular disease (CVD) development. Its pharmacological management is usually based on the prescription of statins, that in some cases are not however fully effective to reach the desired Low-Density-Lipoproteins cholesterol (LDL-C) target, or are not tolerated by patients due to side effects. Areas covered : This manuscript summarizes the basic properties of the emerging new classes of lipid-lowering drugs such as ezetimibe, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors, and Microsomal Triglyceride Transfer Protein (MTP) inhibitors, also citing new drugs in development. Our aim is to describe the main pharmacodynamic and pharmacokinetic characteristics, the available efficacy, tolerability and safety data obtained in randomized clinical trials where these drugs were tested. Expert opinion : Non-statin lipid-lowering drugs can be considered an excellent strategy to reduce the residual CV risk, also represented by non-target LDL-C values and high lipoprotein(a) serum levels. In particular, the approved PCSK9 inhibitors (Evolocumab and Alirocumab) have been very effective in optimizing plasma LDL-C values and reducing CV event risk.